title: Ph+ ALL: drawing strength from a benign past.
abstract: In this issue of Blood, Mallampati et al report on the discovery of a new mechanism of tyrosine kinase inhibitor (TKI) resistance, which is mediated through TKI-mediated priming of mesenchymal stem cells (MSCs) in the bone marrow (BM).
authors.affiliation: UNIVERSITY OF CALIFORNIA SAN FRANCISCO.
authors.forename: Markus
authors.initials: M
authors.lastname: Müschen
mesh_terms: D000818:Animals; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D059630:Mesenchymal Stem Cells / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl